Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
We hypothesized that pretreatment nonresponder and responder liver tissue would show
 consistent differences in gene expression levels and that these differences could be used to
 predict treatment outcomes and this can obviate the need of the present therapeutic trial.We
 are interested in conducting a retrospective study using the data of patients suffering from
 chronic HCV infection who were treated in our department with a combination of PEGINTERFERON
 and RIBAVIRIN. All these patients underwent liver biopsy prior the treatment. Based on the
 clinical data available it is possible to determine the responders and nonresponders to this
 therapy.RNA will be extracted from the liver tissue and the expression of 5
 genes(IFI15,IFI616,IFI1,OAS3,OAS2 )will be checked .The prediction power of the combination
 of these genes in differentiating responders from nonresponders will be determined.
Hepatitis C virus is a leading cause of chronic liver disease, with over 170 million people
 infected worldwide. It is also the leading indication for liver transplantation.
 Complications from chronic hepatitis C infection include cirrhosis, hepatic decompensation,
 and hepatocellular carcinoma. As a result, treatment strategies to prevent such complications
 have been widely researched, although many questions remain unanswered. To date, the standard
 therapy for chronic hepatitis C infection is the combination of peginterferon and
 .ribavirin.A large proportion of patients do not respond to therapy for reasons that are
 unclear. The heterogeneity of viral and host phenotypes makes it unlikely that any single
 factor will accurately predict the cellular response to treatment.It was supposed that liver
 tissue of nonresponder and responder show consistent differences in gene expression levels
 and that these differences could be used to predict treatment outcomes.Hepatic gene
 expression profiling identified consistent differences in patients who subsequently fail
 treatment with pegylated IFN-α plus ribavirin: up-regulation of a specific set of
 IFN-responsive genes predicts nonresponse to exogenous therapy. These data may be of use in
 predicting clinical responses to treatment. 18 genes, confirmed by real-time PCR, with
 expression levels that differed consistently between nonresponders and responders liver
 tissue were detected. Levels for these 18 genes in responders liver were closer to uninfected
 tissue than to nonresponders liver, with a general up-regulation of gene expression in
 nonresponders liver. Many of these genes are IFN responsive, suggesting that the
 nonresponders patients have adopted a different, yet characteristic, equilibrium in their
 host-virus immune response(Chen L et al. Gastroentology 2005:128:1437-1444) We have found a
 method that can predict success or failure of the treatment of chronic hepatitis C based on
 the weighted expression level of a small number of genes (4-5) We derive the genes and their
 decision weights from the microarray data set obtained from the liver biopsy of the patients
 in the above mentioned paper . We would like to test the prediction power of this method in
 an independent set of liver tissues of treated patients in our department.
Inclusion Criteria:

 -  PATIENTS COMPLETING TREATMENT WITH PEGINTERFERON AND RIBAVIRIN FOR CHRONIC HCV
 INFECTION AND UNDERWENT LIVER BIOPSY PRIOR THERAPY ONSET

 Exclusion Criteria:

 -  TREATMENT NOT COMPLETED